CNRS - AIX MARSEILLE UNIV: UMR7257

Home page > en > Research > Teams > Viral Replicases: Structure, function and drug-design

Viral Replicases: Structure, function and drug-design

Head Bruno CANARD

Latest Publications

  1. Metal chelators for the inhibition of the lymphocytic choriomeningitis virus endonuclease domain (2019) Saez-Ayala M, Laban Yekwa E, Mondielli C, Roux L, Hernandez S, Bailly F, Cotelle P, Rogolino D, Canard B, Ferron F, Alvarez K. Antiviral Res. 162 79-89 PMID:30557576
  2. Identification of a new natural gastric lipase inhibitor from star anise. (2019) Kamoun J, Rahier R, Sellami M, Koubaa I, Mansuelle P, Lebrun R, Berlioz-Barbier A, Fiore M, Alvarez K, Abousalham A, Carriere F, Aloulou A. Food Funct 10 469-478 PMID:30632597
  3. C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system. (2019) Jais PH, Decroly E, Jacquet E, Le Boulch M, Jais A, Jean-Jean O, Eaton H, Ponien P, Verdier F, Canard B, Goncalves S, Chiron S, Le Gall M, Mayeux P, Shmulevitz M. Nucleic Acids Res in press PMID:30726994
  4. Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay. (2019) Ferreira-Ramos AS, Li C, Eydoux C, Contreras JM, Morice C, Querat G, Gigante A, Perez Perez MJ, Jung ML, Canard B, Guillemot JC, Decroly E, Coutard B. Antiviral Res in press PMID:30639438
  5. FTSJ3 is an RNA 2'-O-methyltransferase recruited by HIV to avoid innate immune sensing. (2019) Ringeard M, Marchand V, Decroly E, Motorin Y, Bennasser Y. Nature in press PMID:30626973
  6. [Ebola virus L protein harbors a new enzymatic activity involved in the internal methylation of RNAs]. (2018) Martin B, Valle C, Coutard B, Canard B, Debart F, Decroly E. Med Sci (Paris) 34 919-921 PMID:30526829
...All publications

Our team seeks to unravel the molecular mechanisms of emerging viruses by characterizing the structures and the enzymatic activities of proteins forming the viral replication and transcription complex. These studies are a prerequisite for the development of specific inhibitors of these enzymes and should allow the development of new antiviral strategies.

RNA viruses are often associated with the emergence of infectious diseases. Among the best known, epidemics related to Ebola, SARS coronavirus and MERS, chikungunya or dengue virus illustrate the worldwide public health concern related to viral infections. The team "Viral replicase: structure, mechanism and drug-design" characterizes enzymes and proteines from emerging viruses involved in the replication of their genome and transcription of their messenger RNAs. These enzymes are associated in a replication/transcription complex (RTC). Our studies focus not only on viral polymerases that are at the heart viral replication, but also on the enzymes involved in RNA modifications such as capping and proofreading and proteins involved in the regulation of replication. Beyond the study of the RTC, we are also interested in the interplay of these enzymes with the innate immunity defence mechanism of the cell. The viral replication proteins are privileged antiviral targets and understanding of their structure and function is essential for the design of antiviral molecules with a high potential. To support these research projects, the lab benefits from the support of an inhibitor-screening platform (PCML) and a platform dedicated to the expression of recombinant viral proteins.


Karine ALVAREZ
Bruno CANARD
Etienne DECROLY
Cécilia EYDOUX
Véronique FATTORINI
François FERRON
Jean-Claude GUILLEMOT
Sergio HERNANDEZ
Rafik KACI
Nhung LE
Philippe LIEUTAUD
Ana-Theresa MORAIS
Thi Hong Van NGUYEN
Oney ORTEGA-GRANDA
Nicolas PAPAGEORGIOU
Nadia RABAH
Barbara SELISKO
Ashleigh SHANNON
Priscila SUTTO-ORTIZ
Coralie VALLE

© AFMB UMR7257  W3C validation